NOVN - Novan, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.7000
-0.0500 (-1.82%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.7500
Open2.7600
Bid0.0000 x 1000
Ask0.0000 x 2200
Day's Range2.6800 - 2.8886
52 Week Range0.6500 - 3.2400
Volume69,809
Avg. Volume475,140
Market Cap70.388M
Beta (3Y Monthly)1.82
PE Ratio (TTM)N/A
EPS (TTM)-0.5560
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Trade prices are not sourced from all markets
  • GlobeNewswire7 days ago

    Novan Expands External Business Partner Network

    Novan, Inc. ("the Company" or "Novan") (NOVN) today announced continued business advancements in both formulation science and manufacturing. Novan has expanded its relationship with MedPharm Ltd (“MedPharm”).

  • GlobeNewswire13 days ago

    Novan to Participate in JMP Securities Life Sciences Conference

    Novan, Inc. ("the Company" or "Novan") (NOVN) today announced that it will participate in the 2019 JMP Securities Life Sciences Conference in New York on Thursday, June 20, 2019. Participation will include a fireside chat as well as a Q&A session. The fireside chat will occur on June 20, 2019 at 9:30 a.m. Eastern.

  • GlobeNewswire20 days ago

    Novan Achieves Compliance with Nasdaq Listing Rule 5450(b)(2)(A)

    Novan, Inc. ("the Company" or "Novan") (NOVN) today announced it has received notification from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Listing Rule 5450(b)(2)(A). This rule requires a minimum $50 million market value of listed securities in order to maintain a listing on The Nasdaq Global Market. The Company previously received a non-compliance notification from Nasdaq on January 14, 2019.

  • GlobeNewswire22 days ago

    First Patient Enrolled and Dosed in Novan’s SB206 Phase 3 Molluscum Program

    Novan, Inc. ("the Company" or "Novan") (NOVN) today announced that the first patient has been dosed in the Company’s “B-SIMPLE” (Berdazimer Sodium In Molluscum Patients with Lesions) Phase 3 program. The study is designed to evaluate topical nitric oxide product candidate SB206 for the treatment of molluscum contagiosum. The B-SIMPLE Phase 3 program consists of two multi-center, randomized, double-blind, vehicle-controlled studies, B-SIMPLE1 and B-SIMPLE2.

  • GlobeNewswire26 days ago

    Novan Announces 2019 Annual Meeting of Stockholders for July 31, 2019

    Novan, Inc. ("the Company" or "Novan") (NOVN) today announced that it will hold its 2019 Annual Meeting of Stockholders on Wednesday, July 31, at 9:30 am Eastern Time, at the Company’s corporate headquarters located at 4105 Hopson Road, Morrisville, NC 27560. Stockholders of record as of the close of business on June 7, 2019 are entitled to notice of and to vote at the 2019 Annual Meeting. The date of the 2019 Annual Meeting represents a change of more than 30 days from the anniversary of the Company’s 2018 Annual Meeting.

  • Executive Voice: She raises cash, and hope, for struggling Novan
    American City Business Journals27 days ago

    Executive Voice: She raises cash, and hope, for struggling Novan

    When Paula Brown Stafford – an accomplished life sciences executive who spent the better part of three decades at Quintiles – took over as president and chief operating officer of Novan (Nasdaq: NOVN), the situation at the company was far from ideal.  The Morrisville drug company has been battling to advance its pipeline of drugs treating skin disorders without the use of antibiotics, but its runway was getting short. Just weeks afterward, Nasdaq sent the company a letter informing it that Novan’s value had dropped so low it would be delisted in July – unless it could raise the stock’s value to higher than $1.92 per share.

  • With a fresh $30 million, Durham pharma set to expand drug pipeline
    American City Business Journalslast month

    With a fresh $30 million, Durham pharma set to expand drug pipeline

    With a $30 million investment from a single Cary-based firm, one Durham pharmaceutical company is "set loose" to run multiple trials.

  • GlobeNewswire2 months ago

    Novan to Present Clinical Data at Annual Meeting of the Society for Investigative Dermatology

    Novan, Inc. ("the Company" or "Novan") (NOVN) today announced that recent data from the Company’s Phase 1b trial with SB414 cream for the treatment of atopic dermatitis and Phase 2 trial with SB206 gel for the treatment of molluscum contagiosum will be presented at the 77th Annual Meeting of the Annual Meeting of the Society for Investigative Dermatology. Clinical and biomarker results from the Company’s Phase 1b atopic dermatitis trial will be presented during an oral presentation on May 9, 2019 and during a poster session on May 11, 2019.

  • Novan adds more cash, now confident it can execute
    American City Business Journals2 months ago

    Novan adds more cash, now confident it can execute

    In an continued effort to fund the company without hurting its already-down stock value, Novan has announced another $12 million deal to forward its lead drug trials.

  • GlobeNewswire2 months ago

    Novan Completes Funding Transaction with Ligand Pharmaceuticals

    Novan, Inc. ("the Company" or "Novan") (NOVN) today announced that the Company has secured $12 million in non-dilutive capital from Ligand Pharmaceuticals Incorporated (“Ligand”) (LGND). This transaction further enables the accelerated advancement of the molluscum Phase 3 program within the overall Novan mid-to-late stage clinical development portfolio. Under the terms of this development funding and royalty agreement, Ligand will provide funding of $12 million in exchange for a tiered royalty of 7 to 10% which will be based on future North American sales of SB206 for the molluscum indication.

  • GlobeNewswire2 months ago

    Novan Confirms Corporate Update Conference Call and Webcast

    Novan, Inc. ("the Company" or "Novan") (NOVN) today confirmed that the Company will host a conference call tomorrow, Thursday, May 2, 2019 at 8:15 am Eastern Time to provide an update on the Company’s recent financing, clinical development plan and business model.

  • Cash-starved Novan adds capital, but at a price
    American City Business Journals2 months ago

    Cash-starved Novan adds capital, but at a price

    With just a over a month of its cash runway left, Novan has come up big with $35 million – but that capital comes with strings attached.

  • GlobeNewswire2 months ago

    Novan Secures Up to $35 Million in Non-Dilutive Funding

    Novan, Inc. ("the Company" or "Novan") (NOVN) today announced that the Company has secured up to $35 million in non-dilutive capital to advance Novan’s late-stage dermatology assets. Of this, $25 million is available immediately and $10 million is contingent upon achieving positive Phase 3 clinical trial results for molluscum contagiosum. This funding will allow Novan to immediately initiate the pivotal Phase 3 molluscum program.

  • Novan stock plummets as Durham company searches for additional financing
    American City Business Journals3 months ago

    Novan stock plummets as Durham company searches for additional financing

    One of the Triangle’s public companies continues to face hardships, as Novan’s stock dives away from the value it needs to stay on the stock exchange.

  • Will NOVAN INC (NOVN) Report Negative Q4 Earnings? What You Should Know
    Zacks3 months ago

    Will NOVAN INC (NOVN) Report Negative Q4 Earnings? What You Should Know

    NOVAN INC (NOVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire3 months ago

    Novan and Sato Advance Japan Market and Dermatology Partnership

    Novan, Inc. ("the Company" or "Novan") (NOVN) today announced that the Company has named Dr. Elizabeth Messersmith, the Company’s Senior Vice President and Chief Development Officer, the chairperson of the Joint Committee responsible for overseeing the Company’s alliance with Sato Pharmaceutical Co., Ltd. (“Sato”).

  • GlobeNewswire4 months ago

    Novan Completes End-of-Phase 2 Meeting and Provides Additional Business Updates

    Novan, Inc. ("the Company" or "Novan") (NOVN) today announced a number of recent business advancements. Novan concluded an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) regarding SB206 for the treatment of molluscum.

  • GlobeNewswire4 months ago

    Novartis Cosentyx® shows superior improvements in psoriasis patients' quality of life versus Janssen's IL-23 Stelara®*

    New CLARITY data show over two-thirds of Cosentyx (secukinumab) treated patients with moderate to severe psoriasis reported no impact of skin disease on their quality of life (QoL) up to Week 16 compared ...

  • GlobeNewswire4 months ago

    Novartis data confirm rapid response and high efficacy of Cosentyx® in psoriasis patients for first time in China

    Phase III study shows close to 9/10 patients who received Cosentyx® 300mg achieved clear or almost clear skin during the first 16 weeks of treatment (87%), with rapid onset of relief seen as early as week ...

  • GlobeNewswire4 months ago

    Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting

    Shareholders approve 22 nd consecutive dividend increase to CHF 2.85 (+2%) per share for 2018; representing a 3.1% yield and approximately 57% payout of free cash flow   Overwhelming majority of shareholders ...

  • GlobeNewswire4 months ago

    Novartis issues summary financial information for the Alcon eye care business ahead of shareholder vote on proposed spin-off

    Basel, February 25, 2019 - Novartis today published certain key financial information for the Alcon eye care business covering the full year 2018 ahead of a vote on the proposed 100% spin-off of Alcon ...

  • GlobeNewswire4 months ago

    Novartis to pursue transformational therapy to reduce risk of cardiovascular disease in people living with elevated levels of inherited lipoprotein(a)

    Novartis announced today that it is exercising its option to license the rights to develop and commercialize TQJ230, an investigational agent previously known as AKCEA-APO(a)-LRx, from Akcea Therapeutics, ...